APOE and Alzheimer disease: APOE4 carriers who took imipramine also had a significantly decreased incidence of conversion to a worse clinical diagnosis (from NC to MCI or from MCI to AD) compared to APOE4 non-carriers (P = 0.0474) (Table 2).